Can't fill your Cladribine (Mavenclad) prescription? Here are real alternative MS treatments your doctor may consider, including Fingolimod, Dimethyl Fumarate, and more.
Maybe your insurance denied coverage. Maybe the specialty pharmacy is backordered. Or maybe the cost — which can top $99,500 per treatment course — is simply out of reach. Whatever the reason, if you can't fill your Cladribine prescription, you need to know your options.
The good news: there are several effective alternatives for relapsing multiple sclerosis. In this post, we'll cover what Cladribine is, how it works, and which medications your doctor might consider as a substitute.
Cladribine (brand name Mavenclad) is a disease-modifying therapy (DMT) approved by the FDA in 2019 for relapsing forms of multiple sclerosis in adults. It's classified as a purine antimetabolite — a type of drug originally developed for cancer treatment that was found to be effective against MS.
Mavenclad is an oral tablet (10 mg) taken in short courses: just 8-20 days of treatment spread across two years. After that, no additional MS treatment may be needed for years. This makes it appealing for patients who want to avoid daily pills or monthly infusions.
Cladribine works by selectively depleting B lymphocytes and T lymphocytes — the immune cells that attack the protective myelin coating around nerves in MS. Once inside these cells, Cladribine is converted into an active form that disrupts DNA synthesis and triggers cell death (apoptosis).
The result is a "reset" of the immune system's overactive response. Lymphocyte levels gradually recover over months, but the disease-modifying effect can last well beyond the treatment period. For a deeper dive, read our post on how Cladribine works.
If Cladribine isn't an option for you right now, talk to your neurologist about these alternatives. Each works differently and has its own pros and cons.
What it is: An oral capsule taken once daily. Fingolimod was the first oral DMT approved for MS (2010).
How it works: Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator. It traps lymphocytes in lymph nodes, preventing them from reaching the brain and spinal cord where they cause damage.
Pros: Oral, once-daily dosing. Well-studied with over a decade of real-world data. Generic versions are available, which can significantly reduce cost.
Cons: Requires first-dose monitoring (6+ hours) for heart rate effects. Ongoing daily medication, unlike Cladribine's short-course approach. Can cause macular edema, liver enzyme elevation, and increased infection risk.
Approximate cost: $8,000-$10,000/month for brand; generic Fingolimod may be $3,000-$6,000/month without insurance.
What it is: An oral capsule taken twice daily. Approved for relapsing MS in 2013.
How it works: Dimethyl Fumarate activates the Nrf2 pathway, which has anti-inflammatory and antioxidant effects. It also reduces the number of immune cells that cross into the central nervous system.
Pros: Oral dosing. Generally well-tolerated after the first few weeks. Multiple generics available (Diroximel Fumarate is a related option with fewer GI side effects).
Cons: Twice-daily dosing. Common GI side effects (flushing, nausea, diarrhea), especially in the first month. Can cause lymphopenia with long-term use. Rare risk of PML (progressive multifocal leukoencephalopathy).
Approximate cost: Generic Dimethyl Fumarate is approximately $1,500-$4,000/month without insurance.
What it is: An oral tablet taken once daily. Approved for relapsing MS in 2012.
How it works: Teriflunomide inhibits an enzyme called dihydroorotate dehydrogenase, which is essential for the rapid division of activated lymphocytes. This slows the immune attack on myelin.
Pros: Simple once-daily oral dosing. Generics available, making it one of the more affordable oral MS treatments.
Cons: Teratogenic (can cause birth defects) — requires a washout procedure before pregnancy. Can cause hair thinning, liver enzyme elevation, and GI symptoms. Considered a lower-efficacy DMT compared to Cladribine.
Approximate cost: Generic Teriflunomide is approximately $1,000-$3,000/month without insurance.
What it is: An intravenous (IV) infusion given every 6 months. Approved for both relapsing MS and primary progressive MS in 2017.
How it works: Ocrelizumab is a monoclonal antibody that targets CD20-positive B cells, depleting them to reduce inflammation. Like Cladribine, it's considered a high-efficacy DMT.
Pros: Just two infusions per year. High efficacy, similar to Cladribine. Approved for primary progressive MS (Cladribine is not). Well-established safety profile.
Cons: Requires IV infusion at a clinic or infusion center (not oral). Infusion reactions are common. Increased risk of infections and potential cancer risk with long-term use.
Approximate cost: Approximately $65,000-$70,000/year at list price. A subcutaneous version (Ocrevus Zunovo) was approved in 2024.
The best alternative depends on your specific situation:
Always discuss these decisions with your neurologist. Switching MS medications requires careful planning, including monitoring lymphocyte counts and timing the transition.
Not being able to fill your Cladribine prescription is frustrating — especially when you know it's the treatment your doctor recommended. But you have options. From oral alternatives like Fingolimod and Dimethyl Fumarate to high-efficacy infusions like Ocrelizumab, there's likely a path forward.
In the meantime, don't give up on finding Cladribine. Check Medfinder for real-time availability, explore savings programs, and work with your doctor to stay on top of your MS treatment.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
